Rege Nephro: A CiRA Spin-Off Pioneering iPS Cell Therapies for Kidney Disease

Professor Kenji Osafune, a nephrologist by training and faculty member at Kyoto University's Center for iPS Cell Research and Application (CiRA), founded Rege Nephro Co., Ltd.查看公司主页 in 2019 with a singular mission: to deliver new treatment options to the millions of patients suffering from kidney diseases. The startup represents a deliberate shift away from the constraints of conventional pharmaceutical partnerships toward a model that can pursue truly ambitious regenerative medicine goals.

The impetus for founding the company emerged from Osafune's firsthand clinical experience. "I am a nephrologist by training and have treated many patients who struggle greatly from kidney diseases," Osafune stated. Beginning his research into kidney regeneration in 2000, he spent six years from 2009 conducting joint research with a major Japanese pharmaceutical company. Although the collaboration yielded promising data toward cell therapies for kidney disease, the project was ultimately discontinued. "Pharmaceutical companies find it difficult to invest in technologies that do not present a clear path towards commercialization within a few years," Osafune explained.

From Academic Research to Startup Formation

The path to incorporation began when Osafune applied for and was selected by Kyoto University's startup incubation program. Recognizing the need for experienced leadership, he recruited a CEO through personal connections—someone with prior experience at a major multinational pharmaceutical company who embraced the vision of building a startup focused on kidney disease treatments.

Monthly meetings covering business planning, human resources, and fundraising strategies preceded the company's official establishment in 2019. In the subsequent fundraising period, Osafune traveled to Tokyo approximately three times per week, meeting with four to five companies daily. "I believe I met with nearly all venture capital firms in Japan, as well as corporate venture capital groups, continuously explaining our business plan," he noted. These efforts successfully secured the necessary funding from Japanese investors.

Therapeutic Pipeline and Technology Platform

Rege Nephro's core technology leverages iPS cells to generate nephron progenitor cells (搜索)搜索该靶点—the building blocks of the kidney—for transplantation as a cell therapy. Preclinical studies have shown that these cells exert protective effects on the kidney. When administered beneath the renal capsule in mice, the therapy suppressed the decline of kidney function. The company anticipates that a single administration could delay the need for dialysis by several years.

The economic implications are substantial. With approximately 20 million patients in Japan living with chronic kidney disease (搜索)搜索该疾病, the cell therapy is designed to be provided at a lower cost than conventional cell therapies, potentially reducing the economic burden of medical care compared to dialysis. The goal is to offer a treatment option that does not rely on dialysis or kidney transplantation.

Beyond kidney disease, Rege Nephro has identified a novel drug candidate for autosomal dominant polycystic kidney disease (搜索)搜索该疾病 (ADPKD) and initiated clinical trials in April 2024. The company's pipeline also extends to diabetes (搜索)搜索该疾病—using pancreatic cells derived from iPS cells—and liver diseases including cirrhosis, through the generation of transplantable hepatocytes and liver tissues. Drug development for metabolic dysfunction–associated steatohepatitis (搜索)搜索该疾病 (MASH) is also underway. The ultimate ambition, according to Osafune, is "to generate whole transplantable kidneys, pancreata, and livers from iPS cells."

Navigating Dual Roles and Fundraising Challenges

Osafune serves as a member of the Board of Directors and Chief Scientific Advisor at Rege Nephro, participating in monthly board meetings and bi-monthly R&D progress meetings. In accordance with Kyoto University regulations, he devotes several hours per month to startup activities—not exceeding eight hours per week—to ensure his academic research is not compromised.

Conflict of interest management remains paramount. "It is essential never to disclose academic research results exclusively to one's own company," Osafune emphasized, noting the careful separation required between his roles, even extending to distinguishing travel purposes.

Fundraising for regenerative medicine clinical trials presents ongoing challenges. Investment trends vary significantly by country and fluctuate over time. "In the United States, for example, investment interest in cell therapy has been declining, making capital more difficult to secure," Osafune observed. While Japan maintains relatively strong attention on regenerative medicine, the field remains difficult to evaluate, leading to investor caution.

Timeline and Future Vision

With the company established in 2019, Rege Nephro aims to initiate portions of clinical trials by approximately 2029, generate concrete data, and create a pathway for transfer to major pharmaceutical companies. An immediate goal is to begin clinical trials of cell therapy for kidney disease by 2027.

"Even conventional drug development takes more than 20 years, and cell therapy is even more complex, requiring stringent quality control, safety assurance, and regulatory compliance," Osafune said. He called on the public to maintain enthusiasm and support for iPS cell research.

The broader vision extends beyond individual therapies. By enabling kidney disease patients to avoid dialysis, medical expenses decrease significantly, and patients who can continue working contribute to a more prosperous society. "We also aspire to export new therapies from Japan to the world, thereby contributing to the enrichment of Japanese society," Osafune concluded.